DK0828513T3 - Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister - Google Patents

Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister

Info

Publication number
DK0828513T3
DK0828513T3 DK95918111T DK95918111T DK0828513T3 DK 0828513 T3 DK0828513 T3 DK 0828513T3 DK 95918111 T DK95918111 T DK 95918111T DK 95918111 T DK95918111 T DK 95918111T DK 0828513 T3 DK0828513 T3 DK 0828513T3
Authority
DK
Denmark
Prior art keywords
parkinsonism
treatment
selective nmda
nmda antagonists
combination preparations
Prior art date
Application number
DK95918111T
Other languages
English (en)
Inventor
Bertrand L Chenard
Frank S Menniti
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0828513T3 publication Critical patent/DK0828513T3/da

Links

Classifications

    • GPHYSICS
    • G10MUSICAL INSTRUMENTS; ACOUSTICS
    • G10HELECTROPHONIC MUSICAL INSTRUMENTS; INSTRUMENTS IN WHICH THE TONES ARE GENERATED BY ELECTROMECHANICAL MEANS OR ELECTRONIC GENERATORS, OR IN WHICH THE TONES ARE SYNTHESISED FROM A DATA STORE
    • G10H5/00Instruments in which the tones are generated by means of electronic generators
    • G10H5/10Instruments in which the tones are generated by means of electronic generators using generation of non-sinusoidal basic tones, e.g. saw-tooth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Multimedia (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
DK95918111T 1995-05-26 1995-05-26 Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister DK0828513T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB1995/000398 WO1996037226A2 (en) 1995-05-26 1995-05-26 Combinations for the treatment of parkinsonism containing selective nmda antagonists
HU9601419A HUP9601419A3 (en) 1995-05-26 1996-05-24 Synergetic pharmaceutical compositions for treating parkinson-disease

Publications (1)

Publication Number Publication Date
DK0828513T3 true DK0828513T3 (da) 2004-04-13

Family

ID=89994003

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95918111T DK0828513T3 (da) 1995-05-26 1995-05-26 Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister

Country Status (26)

Country Link
US (1) US6258827B1 (da)
EP (1) EP0828513B1 (da)
JP (1) JPH11505828A (da)
CN (1) CN1159325A (da)
AT (1) ATE258067T1 (da)
AU (1) AU696258B2 (da)
BR (1) BR9602485A (da)
CA (1) CA2219911C (da)
CO (1) CO4700422A1 (da)
CZ (1) CZ283979B6 (da)
DE (1) DE69532482T2 (da)
DK (1) DK0828513T3 (da)
ES (1) ES2211904T3 (da)
FI (1) FI974323A (da)
HU (1) HUP9601419A3 (da)
IL (1) IL118328A (da)
MX (1) MX9709112A (da)
NO (1) NO962130L (da)
NZ (1) NZ286656A (da)
PL (1) PL314413A1 (da)
PT (1) PT828513E (da)
RU (1) RU2176145C2 (da)
SG (1) SG45479A1 (da)
TR (1) TR199600436A2 (da)
TW (1) TW470740B (da)
WO (1) WO1996037226A2 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
HUP0004900A3 (en) * 1997-10-24 2002-03-28 Warner Lambert Co Pharmaceutical compositions for treating disease-related or drug-induced dyskinesias containing piperidine derivatives as nmda receptor antagonist as active ingredient
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
EP1235572A2 (en) 1999-10-29 2002-09-04 MERCK SHARP & DOHME LTD. Method to treat pain utilizing benzimidazole nmda/nr2b antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
DK1379520T3 (da) 2001-02-23 2006-08-21 Merck & Co Inc N-substituerede ikke-aryl-heterocykliske NMDA/NR2B-antagonister
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH
EP1390034A4 (en) 2001-04-03 2005-07-13 Merck & Co Inc NMDA / NR2B NONARYL-HETEROCYCLO AMIDYL N-SUBSTITUTE ANTAGONISTS
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10142176A1 (de) * 2001-08-29 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten
EP1472248A1 (en) * 2002-01-17 2004-11-03 Eli Lilly And Company Modulators of acetylcholine receptors
US6743921B2 (en) 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
BR0314541A (pt) * 2002-10-08 2005-07-26 Allergan Inc Tratamento de demência e doença de parkinson
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
CA2537765A1 (en) * 2003-09-04 2005-03-17 Board Of Regents, The University Of Texas System Methods and compositions for the prevention and treatment of genitourinary disorders, including pre-term labor and leiomyomas
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
US20060240043A1 (en) * 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP2008526923A (ja) * 2005-01-13 2008-07-24 ノイロサーチ アクティーゼルスカブ 新規8−置換8−アザ−ビシクロ[3.2.1]オクタン誘導体及びモノアミン神経伝達物質再取り込み阻害剤としてのそれらの使用
PL1874282T3 (pl) 2005-04-06 2011-04-29 Adamas Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń OUN
US20070118044A1 (en) * 2005-07-18 2007-05-24 Mega Elektroniikka Oy Method and device for identifying; measuring and analyzing abnormal neurological responses
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
RU2324492C1 (ru) * 2006-12-04 2008-05-20 Общество с ограниченной ответственностью "Березовый мир" Средство для профилактики и лечения болезни паркинсона
EP2170334B1 (en) * 2007-06-29 2021-03-17 Emory University Nmda receptor antagonists for neuroprotection
RU2540470C9 (ru) * 2008-06-06 2015-07-20 Фарма Ту Б Лтд. Фармацевтические композиции для лечения болезни паркинсона
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
EP2838530B1 (en) * 2012-04-20 2017-04-05 UCB Biopharma SPRL Methods for treating parkinson's disease
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
RS65060B1 (sr) 2014-03-13 2024-02-29 Neuroderm Ltd Sastavi inhibitora dopa dekarboksilaze
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
US5356905A (en) 1990-02-06 1994-10-18 Pfizer Inc. Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
HUT65836A (en) 1991-04-18 1994-07-28 Pfizer Process for producing phenol-esters of 1-(hydroxy-phenyl)-2-piperidino-1-alkanol derivatives and pharmaceutical compositions containing them
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson

Also Published As

Publication number Publication date
IL118328A (en) 2001-06-14
FI974323A0 (fi) 1997-11-25
ES2211904T3 (es) 2004-07-16
EP0828513B1 (en) 2004-01-21
RU2176145C2 (ru) 2001-11-27
SG45479A1 (en) 1998-01-16
CO4700422A1 (es) 1998-12-29
HUP9601419A3 (en) 1998-01-28
NO962130L (no) 1996-11-27
MX9709112A (es) 1998-02-28
TW470740B (en) 2002-01-01
FI974323A (fi) 1997-11-25
PT828513E (pt) 2004-05-31
WO1996037226A2 (en) 1996-11-28
TR199600436A2 (tr) 1996-12-21
PL314413A1 (en) 1996-12-09
CZ283979B6 (cs) 1998-07-15
IL118328A0 (en) 1996-09-12
CN1159325A (zh) 1997-09-17
ATE258067T1 (de) 2004-02-15
BR9602485A (pt) 1998-04-22
WO1996037226A3 (en) 1996-12-27
DE69532482D1 (de) 2004-02-26
EP0828513A2 (en) 1998-03-18
AU5451996A (en) 1996-12-05
US6258827B1 (en) 2001-07-10
HU9601419D0 (en) 1996-07-29
JPH11505828A (ja) 1999-05-25
HUP9601419A2 (en) 1997-09-29
NZ286656A (en) 2001-03-30
CA2219911A1 (en) 1996-11-28
CA2219911C (en) 2004-07-27
AU696258B2 (en) 1998-09-03
DE69532482T2 (de) 2004-11-25
CZ152496A3 (cs) 1998-04-15
NO962130D0 (no) 1996-05-24

Similar Documents

Publication Publication Date Title
DK0828513T3 (da) Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
DE60022050T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
ATE230989T1 (de) Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
IL128723A0 (en) Pharmaceutical compositions containing rar antagonists and rxr agonists
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DK0840601T3 (da) THIP til behandling af søvnforstyrrelser
ATE144898T1 (de) Behandlung neurodegenerativer krankheiten
ATE256671T1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
EA200401230A1 (ru) Азабициклические, азатрициклические и азаспироциклические производные аминоциклогексана в качестве антагонистов рецепторов nmda, 5ht и нейронных никотиновых рецепторов
DE69926794D1 (de) Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen
MY118944A (en) Synergistic treatment for parkinsonism
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
SE9501773D0 (sv) New use